Immuron Ltd - Asset Resilience Ratio

Latest as of June 2025: 29.97%

Immuron Ltd (IMC) has an Asset Resilience Ratio of 29.97% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

AU$3.04 Million
≈ $2.15 Million USD Cash + Short-term Investments

Total Assets

AU$10.13 Million
≈ $7.17 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2000–2025)

This chart shows how Immuron Ltd's Asset Resilience Ratio has changed over time. Check Immuron Ltd strategic capital allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets Composition Over Time

This chart breaks down Immuron Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see IMC company net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents AU$0.00 0%
Short-term Investments AU$3.04 Million 29.97%
Total Liquid Assets AU$3.04 Million 29.97%

Asset Resilience Insights

  • Very High Liquidity: Immuron Ltd maintains exceptional liquid asset reserves at 29.97% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Immuron Ltd Industry Peers by Asset Resilience Ratio

Compare Immuron Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
Sk Biopharmaceuticals Co Ltd
KO:326030
Biotechnology 0.14%
Tango Therapeutics Inc
NASDAQ:TNGX
Biotechnology 57.90%
TELIX Pharmaceuticals Ltd
AU:TLX
Biotechnology 32.29%
Xiamen Amoytop Biotech Co Ltd
SHG:688278
Biotechnology 4.69%
Hangzhou Biotest Biotech Co Ltd
SHG:688767
Biotechnology 0.56%
Theravance Biopharma Inc
F:0TB
Biotechnology 37.29%

Annual Asset Resilience Ratio for Immuron Ltd (2000–2025)

The table below shows the annual Asset Resilience Ratio data for Immuron Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 29.97% AU$3.04 Million
≈ $2.15 Million
AU$10.13 Million
≈ $7.17 Million
--
2024-06-30 0.00% AU$0.00
≈ $0.00
AU$15.55 Million
≈ $11.00 Million
--
2023-06-30 8.34% AU$1.83 Million
≈ $1.30 Million
AU$21.99 Million
≈ $15.56 Million
+0.96pp
2022-06-30 7.38% AU$1.83 Million
≈ $1.30 Million
AU$24.86 Million
≈ $17.59 Million
-43.77pp
2018-06-30 51.15% AU$4.73 Million
≈ $3.34 Million
AU$9.24 Million
≈ $6.54 Million
+2.94pp
2017-06-30 48.21% AU$3.99 Million
≈ $2.83 Million
AU$8.29 Million
≈ $5.86 Million
--
2016-06-30 0.00% AU$0.00
≈ $0.00
AU$8.83 Million
≈ $6.25 Million
--
2006-06-30 16.60% AU$1.10 Million
≈ $778.32K
AU$6.63 Million
≈ $4.69 Million
-26.59pp
2005-06-30 43.19% AU$3.48 Million
≈ $2.46 Million
AU$8.05 Million
≈ $5.70 Million
+22.83pp
2004-06-30 20.37% AU$1.00 Million
≈ $707.56K
AU$4.91 Million
≈ $3.47 Million
-15.40pp
2003-06-30 35.77% AU$2.13 Million
≈ $1.51 Million
AU$5.96 Million
≈ $4.21 Million
-6.81pp
2002-06-30 42.57% AU$2.80 Million
≈ $1.98 Million
AU$6.58 Million
≈ $4.65 Million
-15.35pp
2001-06-30 57.92% AU$4.54 Million
≈ $3.21 Million
AU$7.83 Million
≈ $5.54 Million
-30.91pp
2000-06-30 88.83% AU$4.00 Million
≈ $2.83 Million
AU$4.50 Million
≈ $3.19 Million
--
pp = percentage points

About Immuron Ltd

AU:IMC Australia Biotechnology
Market Cap
$8.32 Million
AU$11.76 Million AUD
Market Cap Rank
#27502 Global
#1359 in Australia
Share Price
AU$0.04
Change (1 day)
+0.00%
52-Week Range
AU$0.03 - AU$0.09
All Time High
AU$0.86
About

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal d… Read more